Rebecca Bilardi

HBO1 is required for the maintenance of leukaemia stem cells

Laura MacPherson, Juliana Anokye, Miriam M Yeung, Enid YN Lam, Yih-Chih Chan, Chen-Fang Weng, Paul Yeh, Kathy Knezevic, Miriam S Butler, Annabelle Hoegl, Kah-Lok Chan, Marian L Burr, Linden J Gearing, Tracy Willson, Joy Liu, Jarny Choi, Yuqing Yang, Rebecca A Bilardi, Hendrik Falk, Nguyen Nghi, et al.

Journal article  |  2020  |  Nature

Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional dysregulation that results in a block in..

Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice

Natasha S Anstee, Rebecca A Bilardi, Ashley P Ng, Zhen Xu, Mikara Robati, Cassandra J Vandenberg, Suzanne Cory

Journal article  |  2019  |  CELL DEATH AND DIFFERENTIATION

MOZ (KAT6A) is essential for the maintenance of classically defined adult hematopoietic stem cells

Bilal N Sheikh, Yuqing Yang, Jaring Schreuder, Susan K Nilsson, Rebecca Bilardi, Sebastian Carotta, Helen M McRae, Donald Metcalf, Anne K Voss, Tim Thomas

Journal article  |  2016  |  Blood

Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice

Rebecca A Bilardi, Natasha S Anstee, Stefan P Glaser, Mikara Robati, Cassandra J Vandenberg, Suzanne Cory

Journal article  |  2016  |  Cell Death and Disease

HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia

Gabriela Brumatti, Marika Salmanidis, Chung H Kok, Rebecca A Bilardi, Jarrod J Sandow, Natasha Silke, Kylie Mason, Jolanda Visser, Anissa M Jabbour, Stefan P Glaser, Toru Okamoto, Philippe Bouillet, Richard J D'Andrea, Paul G Ekert

Journal article  |  2013  |  Oncotarget

Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways.

RA Bilardi, K-I Kimura, DR Phillips, SM Cutts

Journal article  |  2012  |  Biochemical Pharmacology

Anthracycline chemotherapeutics are well characterised as poisons of topoisomerase II, however many anthracyclines, including doxo..

M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe

Benny J Evison, Mile Pastuovic, Rebecca A Bilardi, Robert A Forrest, Paul P Pumuye, Brad E Sleebs, Keith G Watson, Don R Phillips, Suzanne M Cutts

Journal article  |  2011  |  BIOCHEMICAL PHARMACOLOGY

New Anthracenedione Derivatives with Improved Biological Activity by Virtue of Stable Drug-DNA Adduct Formation

Oula C Mansour, Benny J Evison, Brad E Sleebs, Keith G Watson, Abraham Nudelman, Ada Rephaeli, Damian P Buck, J Grant Collins, Rebecca A Bilardi, Don R Phillips, Suzanne M Cutts

Journal article  |  2010  |  JOURNAL OF MEDICINAL CHEMISTRY

Drug-DNA adducts formed by formaldehyde activation of anthracyclines and related anti-cancer agents

DR Phillips, L Swift, K Coldwell, D Spencer, R Bilardi, B Evison, O Mansour, A Nudelman, A Rephaeli, TH Koch, SM Cutts

Book Chapter  |  2010

Barminomycin, a model for the development of new anthracyclines.

K Kimura, DMS Spencer, R Bilardi, LP Swift, AJ Box, RTC Brownlee, SM Cutts, DR Phillips

Journal article  |  2010  |  Anti-Cancer Agents in Medicinal Chemistry

Barminomycin is a member of the anthracycline class of anticancer agents and was originally discovered as a pink/red complex with ..